NCT07337109 A Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers
| NCT ID | NCT07337109 |
| Status | Recruiting |
| Phase | — |
| Sponsor | HALEON |
| Condition | Dentin Hypersensitivity |
| Study Type | OBSERVATIONAL |
| Enrollment | 375 participants |
| Start Date | 2025-12-16 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 375 participants in total. It began in 2025-12-16 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary purpose of this study is to characterize changes in Oral-Health-Related Quality of Life (OHrQoL), as measured by the Dentin Hypersensitivity Experience Questionnaire (DHEQ) over a 12-month period.
Eligibility Criteria
Inclusion Criteria: * Participant who has provided consent indicating they have been informed of all pertinent aspects of the study. * All genders who, at the time of screening, are aged more than or equal to (\>=)18 years. * Anyone who has begun to experience dentin hypersensitivity (self-reported) within the past three months. * Anyone who has started to use products to treat their tooth sensitivity within the past three months. * Participant who is able to independently complete all activities online. * Participants residing in the United States. Exclusion Criteria: * Anyone who has any chronic health conditions that could impact their participation in this study, such as cancer, mental health disorders, history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period. * Participant whose sensitivity could be caused by other factors or clinical pathology than DH, as self-reported on the screening questionnaire, which include: 1. Anyone who suffers from tooth cavities, significant gum disease, cracked or fractured teeth, temporomandibular joint disease (TMD), or who has had tooth extractions or fillings within the last three months. 2. Anyone who wears braces (including Invisalign-like appliances) for treatment or dentures (full or partial). 3. Participant who has undergone treatment for periodontal or gum disease within 6 months of screening or is currently undergoing treatment for periodontal or gum disease. 4. Participant who has been informed by a Dental Health Care Professional (DHCP) that they have active periodontitis. 5. Participant who has been informed by a DHCP that they have active caries. 6. Participant with any chronic and/or severe painful health condition(s) which lead to regular use of pain relief medications (more than 3 days a week). * Anyone who has participated in another dentin hypersensitivity study within the last three months. * Currently participating in another research study or will be participating in any other research study at any point during this study's duration.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07337109 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dentin Hypersensitivity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07337109 currently recruiting?
Yes, NCT07337109 is actively recruiting participants. Contact the research team at ww.clinical-trial-register@haleon.com for enrollment information.
Where is the NCT07337109 trial being conducted?
This trial is being conducted at Las Vegas, United States.
Who is sponsoring the NCT07337109 clinical trial?
NCT07337109 is sponsored by HALEON. The trial plans to enroll 375 participants.